Mineralocorticoid Receptor Antagonists

Drugs that bind to and block the activation of MINERALOCORTICOID RECEPTORS by MINERALOCORTICOIDS such as ALDOSTERONE.

Also Known As:

Aldosterone Receptor Antagonists; Mineralocorticoid Antagonists; Antagonist, Aldosterone; Antagonist, Aldosterone Receptor; Antagonist, Mineralocorticoid; Antagonist, Mineralocorticoid Receptor; Antagonists, Aldosterone; Antagonists, Aldosterone Receptor; Antagonists, Mineralocorticoid; Antagonists, Mineralocorticoid Receptor; Receptor Antagonist, Aldosterone; Receptor Antagonist, Mineralocorticoid; Receptor Antagonists, Aldosterone; Receptor Antagonists, Mineralocorticoid; Aldosterone Antagonist; Aldosterone Antagonists; Aldosterone Receptor Antagonist; Mineralocorticoid Antagonist; Mineralocorticoid Receptor Antagonist

Networked: 2014 relevant articles (188 outcomes, 450 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Pitt, Bertram: 108 articles (02/2022 - 05/2002)
2.	Solomon, Scott D: 55 articles (01/2022 - 10/2004)
3.	Zannad, Faiez: 49 articles (01/2022 - 04/2007)
4.	Fonarow, Gregg C: 47 articles (01/2022 - 01/2002)
5.	Pfeffer, Marc A: 44 articles (01/2022 - 10/2004)
6.	Desai, Akshay S: 37 articles (01/2022 - 12/2009)
7.	Rossignol, Patrick: 37 articles (01/2022 - 05/2009)
8.	McMurray, John J V: 33 articles (06/2022 - 10/2004)
9.	Shah, Sanjiv J: 32 articles (11/2021 - 03/2013)
10.	Claggett, Brian: 30 articles (11/2021 - 09/2013)

Related Diseases

1.	Heart Failure 01/01/2011 - "There were marked deficiencies in the prescription of aldosterone antagonists (35%) for severe heart failure, which improved to 44.2% after the intervention. " 01/01/2007 - "Aldosterone antagonists have been proven to be beneficial in severe heart failure (HF) as a result of systolic dysfunction. " 01/01/2022 - "Mineralocorticoid receptor antagonists (MRAs) may be beneficial in reducing heart failure (HF) hospitalizations in patients with HF with preserved ejection fraction. " 02/01/2010 - "Using mineralocorticoid receptor antagonists a significant reduction in mortality was archived in patients with heart failure. " 01/01/2013 - "Aldosterone antagonists have previously been shown to improve survival in a wide spectrum of patients with heart failure with reduced ejection fraction (HFrEF), and more recently, small trials suggested that they might have role in HFpEF patients. "
2.	Hypertension (High Blood Pressure) 01/01/2017 - "Mineralocorticoid-receptor antagonists (MRAs) have proven to be effective in some types of hypertension, especially in resistant hypertension (RHTN). " 11/25/2022 - "At follow-up, pACE2 decreased in surgically treated patients who had (P < .001) or had no (P = .006) hypertension remission, but the pACE2 attenuation was not statistically significant in uPA (P = .085) and bilateral PA (P = .409) administered with mineralocorticoid receptor antagonist (MRA). " 03/01/2021 - "Nevertheless, specific treatment for PA significantly improved cPWV, which argues for a more liberal use of mineralocorticoid receptor antagonists in patients with arterial hypertension." 04/01/2013 - "Among individuals with resistant hypertension, aldosterone antagonists have also been shown to be effective in lowering blood pressure. " 12/01/2009 - "This suggests that aldosterone antagonists may be useful for the treatment of hypertension among AAs, regardless of BMI."
3.	Type 2 Diabetes Mellitus (MODY) 01/01/2021 - "(EU Clinical trials: Mineralocorticoid Receptor Antagonists in Type 2 Diabetes [MIRAD]; 2015-002519-14)." 01/01/2023 - "Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial." 11/22/2023 - "This review provides an overview of the management of chronic kidney disease (CKD) associated with type 2 diabetes (T2D), how the novel treatment class of nonsteroidal mineralocorticoid receptor antagonists (MRAs) fits within the treatment landscape, and how pharmacists can contribute to the multidisciplinary care of patients with CKD associated with T2D. " 01/01/2023 - "Early heart failure prevention is central in patients with type 2 diabetes, and mineralocorticoid receptor antagonists (MRAs) have shown to improve prognosis. " 11/01/2023 - "Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)."
4.	Hyperaldosteronism (Conn Syndrome) 01/01/2018 - "Mineralocorticoid receptor antagonists are recommended as the first-line treatment in patients with bilateral primary aldosteronism. " 08/29/2023 - "This study aimed to compare the efficacy of SAAE with mineralocorticoid receptor antagonists (MRA) in treating patients with idiopathic hyperaldosteronism. " 01/01/2018 - "We conducted an in-depth review of the literature and comprehensive identification of the clinical studies investigating the efficacy of mineralocorticoid receptor antagonists in individuals with primary aldosteronism. " 09/15/2023 - "Following the diagnosis of bilateral primary aldosteronism, we initiated a mineralocorticoid receptor antagonist, which improved his blood pressure. " 01/01/2018 - "The study aimed to assess the effects of mineralocorticoid receptor antagonist in the treatment of patients with primary aldosteronism. "
5.	Chronic Renal Insufficiency 04/01/2016 - "Finereroneholds promise for the future application of this new mineralocorticoid receptor antagonist class in patients with chronic kidney disease since it has shown a significant reduction in UACR combined with a safety profile similar to that in the placebo group. " 01/01/2023 - "The objective of our study is to evaluate the efficacy and safety of mineralocorticoid receptor antagonists (MRAs) and determine the optimal MRA treatment regimen in patients with chronic kidney disease (CKD). " 01/01/2016 - "We conducted a meta-analysis investigating renoprotective effects and risk of hyperkalaemia in trials of mineralocorticoid receptor antagonists in chronic kidney disease. " 09/01/2015 - "Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials." 06/01/2010 - "This trial is expected to show whether a low dose of mineralocorticoid receptor antagonists can exert an antialbuminuric effect in patients with chronic kidney disease."

Related Drugs and Biologics

1.	Spironolactone (Aldactone)
2.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
3.	Eplerenone (Inspra)
4.	finerenone
5.	Aldosterone
6.	Angiotensin Receptor Antagonists
7.	Sodium
8.	Diuretics
9.	Neprilysin (Neutral Endopeptidase)
10.	Glucose (Dextrose)

Related Therapies and Procedures

1.	Therapeutics
2.	Adrenalectomy
3.	Cardiac Resynchronization Therapy
4.	Renal Dialysis (Hemodialysis)
5.	Implantable Defibrillators (Implantable Cardioverter-Defibrillator)